Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel

Girolamo Ranieri, Ilaria Marech, Mariangela Porcelli, Francesco Giotta, Gennaro Palmiotti, Giuseppe Laricchia, Vito Fazio, Cosmo Damiano Gadaleta

Research output: Contribution to journalArticle

Abstract

About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pretreated patients with LMs. Here we report the case of a 55-year-old woman affected by BCLPD and heavily pretreated. LMs responded to treatment based on HAI with 5-fluorouracil and nabpaclitaxel systemic chemotherapy, and they completely disappeared on a CT-scan. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of patients with BCLPD. Therefore, this combination should be evaluated in a large study.

Original languageEnglish
Pages (from-to)8197-8203
Number of pages7
JournalOncotarget
Volume9
Issue number8
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Breast cancer
  • Hepatic intra-arterial chemotherapy
  • Liver metastases
  • Nab-paclitaxel

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel'. Together they form a unique fingerprint.

  • Cite this